Relevium Technologies Inc. (TSX.V: “RLV”, OTC: “RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to
provide an update on all major corporate initiatives and ongoing
disclosure obligations.
UPDATE ON THE FILING OF
AUDITED STATEMES AND FIRST QUARTER
INTERIMS
We are pleased to provide an update to its
previously disclosed management cease trade order ("MCTO"),
announced on October 27, 2020, in respect to the audited annual
financial statements for the year ended June 30, 2020, the interim
financial statements for the first quarter of operations for the
three months ended September 30, 2020 and corresponding
management's discussion and analysis for both filings.
(collectively, the “Required Financial Filings”) that were not
filed by the required filing deadline of October 28, 2020 for the
annual and November 30, 2020 for the interim.
The MCTO will allow the Company to submit the
Required Financial Filings not later than December 27, 2020. As
such, the MCTO will remain in effect until the Required Financial
Filings are completed.
Until the Required Financial Filings are
completed, the Company will issue bi-weekly default status reports
in accordance with National Policy 12-203 - Management Cease Trade
Orders. The Company intends to satisfy the provisions of the
Alternative Information Guidelines during the period it remains in
default of the filing requirements. The Company confirms that there
have been no material business developments or other material
information relating to its affairs as of the date of this news
release that have not been generally disclosed.
Aurelio Useche, CEO of Relevium stated: “The
delays in the filings of the required financials were due to two
major facts. First, the Company engaged new auditors, RSM Canada
LLP, which normally means an additional burden of a learning curve.
The second reason has been the effect of the COVID-19 pandemic on
preparation of the files, new disclosures and valuation
assessments” Mr. Useche further states: “We are working diligently
with our new auditors to complete both periods before the upcoming
holidays”
UPDATE ON THE SUPPLY SIDE OF OUR
CONTRACT FOR PERSONAL PROTECTION SUPPLIES
On September 29, 2020 the Company announced the
start of deliveries of Personal Protective Equipment
(“PPE”) under its contractual obligations to
supply US $20 Million dollars. The delivery of initial product
batches has been subjected to delays related to major logistical
issues outside of the company’s control.
The Company has several outstanding PPE supply
contracts in place and expects to deliver before the end of the
current year. The Company remains cautious about ongoing issues
outside of the company’s control as the global pandemic continues
to influence, not only the demand, but also the supply side and
logistics. The PPE products in question are manufactured and
sourced in Asia and are subject to local Covid-19 restrictions,
affecting both manufacturing and logistics.
Aurelio Useche CEO for Relevium commented as
follows: “The delivery of our PPE supply contracts has been
affected by issues outside of our control. These are difficult
markets to navigate with a high level of risk and uncertainty. The
global demand for PPE products has definitely made it a seller’s
market, where the rules of orderly business conduct and common
sense simply do not apply. We have an extensive team of partners
managing the process, including H-Source Holdings (TSX-V:” HSI”)
and we look forward to meeting our contractual obligations and
commitments”
About Relevium
Technologies
Relevium is a publicly traded Company that
operates in the health and wellness industry with a primary focus
on online distribution. The principal business of the Company is
the identification, evaluation, acquisition and operation of brands
and businesses in the health and wellness markets. The Company
recently entered the PPE business as part of its strategy through
acquisitions and partnerships in a holistic approach to encompass a
wide range of health and wellness consumer products. Relevium
operates through two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based
in Orlando, Florida, markets dietary supplements, nutraceuticals,
sports nutrition, and cosmeceuticals primarily through its
Bioganix® brand portfolio in the US and Europe. Relevium’s premium
brands are sold at some of the world’s largest retailers including
Walmart.com and Amazon.com.
Biocannabix
Health Corporation
(BCX), based in Montreal, Quebec, is a biopharma
nutraceutical Company focused on delivering pediatric
endo-medicinal nutraceuticals for cannabinoid therapy.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking StatementsThis release includes certain
statements and information that may constitute forward-looking
information within the meaning of applicable Canadian and United
States securities laws. All statements in this news release, other
than statements of historical facts, including statements regarding
future estimates, plans, objectives, assumptions, or expectations
of future performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", or "would" occur.
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release. These
forward-looking statements are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of the Company to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors,
AURELIO USECHE |
RELEVIUM TECHNOLOGIES INC. |
President and CEO |
For more information about this press release: |
|
Tel: +1.888.528.8687 |
|
Email:investors@releviumcorp.com |
|
www.releviumtechnologies.com |
|
Facebook |
|
Twitter |
|
LinkedIn |
H Source (TSXV:HSI)
過去 株価チャート
から 10 2024 まで 11 2024
H Source (TSXV:HSI)
過去 株価チャート
から 11 2023 まで 11 2024